MCL1 and sarcoma: As the differential expression of anti-apoptotic proteins (e.g., MCL-1 or BCL-XL) or pro-apoptotic proteins (e.g., BIM, PUMA, or NOXA) can alter sensitivity to BCL-2 inhibition [8,17,25,26,27], we evaluated the expression of BCL2 family transcripts across multiple sarcoma tumor types [20].